TG Therapeutics, Inc. Announces Data Presentations at the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 58th American Society of Hematology Annual Meeting

NEW YORK, Nov. 03, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX ), today announced that updated data for TGR-1202, the Company’s once-daily PI3K delta inhibitor, and TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, have been selected for presentation at the upcoming 58 th American Society of Hematology (ASH) annual meeting, to be held December 3-6, 2016, at the San Diego Convention Center in San Diego, California.

“We are looking forward to an exciting ASH conference as we continue to present data on the differentiation between TGR-1202 and the first generation PI3K delta inhibitors.  With three oral presentations and three poster presentations it is clear the strength of TGR-1202, and our overall UNITY program, is starting to be noticed by leaders in the treatment of B-cell malignancies.  We have seen scientific and clinical interest in our programs continue to grow, and notably all three of the oral presentations at this coming ASH meeting resulted from independent investigator driven interest in working with TGR-1202.  We look forward to sharing this data at the upcoming meeting and expanding on our investigator initiated collaborations while we continue to drive our registration-directed trials toward pivotal data in 2017, potentially leading to our first approval in 2018,” stated Michael S. Weiss, the Company's Executive Chairman and Interim CEO. Presentations at the ASH 2016 meeting include the following:

Oral Presentations:

  • Title: Silencing c-Myc Translation as a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies
    • Abstract Number: 291
    • Oral Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Cell Signaling
    • Date and Time:   Sunday, December 4, 2016; 7:30 AM - 9:00 AM PT
    • Presentation Time: 8:00 AM PT
    • Location: San Diego Convention Center, Room 5AB
    • Presenter: Changchun (George) Deng, MD, PhD, Columbia University, New York, NY
  • Title: TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study
    • Abstract Number: 641
    • Oral Session: 642. CLL: Therapy, excluding Transplantation: Targeted Therapy: Novel Agents and Combinations
    • Date and Time:   Monday, December 5, 2016; 7:00 AM - 8:30 AM PT
    • Presentation Time: 8:00 AM PT
    • Location: San Diego Convention Center, Room 5AB
    • Presenter: Matthew S. Davids, MD, Dana Farber Cancer Institute, Boston, MA  
  • Title: Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis
    • Abstract Number: 1125
    • Oral Session: 634. Myeloproliferative Syndromes: Clinical: Clinical Trials with JAK Inhibitors
    • Date and Time:   Monday, December 5, 2016; 4:30 PM - 6:00 PM PT
    • Presentation Time: 5:00 PM PT
    • Location: Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17
    • Presenter: Tamara Kay Moyo, MD, PhD, Vanderbilt-Ingram Cancer Center, Nashville, TN

Posters Presentations:

  • Title: Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202
    • Abstract Number: 3236
    • Session: 642. CLL: Therapy, excluding Transplantation: Poster II
    • Date and Time:   Sunday, December 4, 2016 6:00 PM - 8:00 PM PT
    • Location: San Diego Convention Center, Hall GH
    • Presenter: Kamira K. Maharaj, BS, Moffit Cancer Center, Tampa, FL  
  • Title: Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma
    • Abstract Number: 4197
    • Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster III
    • Date and Time: Monday, December 5, 2016; 6:00 PM-8:00 PM PT
    • Location: San Diego Convention Center, Hall GH
    • Presenter: Matthew A. Lunning, DO, University of Nebraska Medical Center, Omaha, NE  
  • Title: A Phase I Trial of TGR-1202, a Next Generation Once-Daily PI3Kδ Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma
    • Abstract Number: 4146
    • Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III
    • Date and Time: Monday, December 5, 2016; 6:00 PM-8:00 PM PT
    • Location: San Diego Convention Center, Hall GH
    • Presenter: Rod Ramchandren, MD, Karmanos Cancer Center, Detroit, MI

A copy of the above referenced abstracts can be viewed online through the ASH meeting website at www.hematology.org . Following each presentation, the data presented will be available on the Publications page of the Company’s website at www.tgtherapeutics.com .

TG Therapeutics will also host an investor and analyst reception on Monday, December 5 th , 2016 beginning at 8:00pm PT.  The event will take place at the Marriott Gaslamp, in San Diego, California.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City. Cautionary Statement

Some of the statements included in this press release, particularly those with respect to anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101, TGR-1202, the IRAK4 inhibitor program, the BET inhibitor program, and the anti-PD-L1 and anti-GITR antibodies may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete preclinical and clinical trials for TG-1101, TGR-1202, the IRAK4 inhibitor program, the BET inhibitor program, and the anti-PD-L1 and anti-GITR antibodies; the risk that early preclinical and clinical results that supported our decision to move forward with TG-1101, TGR-1202, the IRAK4 inhibitor program, the BET inhibitor program, and the anti-PD-L1 and anti-GITR antibodies will not be reproduced in additional patients or in future studies; the risk that trends observed which underlie certain assumptions of future performance of TGR-1202 will not continue, the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following the completion of the current Phase 1 study; the risk that the combination of TG-1101 and TGR-1202, referred to as TG-1303, will not prove to be a safe and efficacious backbone for triple and quad combination therapies; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior preclinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com . The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

TGTX - G

CONTACT: Jenna Bosco Vice President, Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email: ir@tgtxinc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 8

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 101

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
A Faded Sign Is a Quiet Leak in Storefront Demand Today

Updated Category News Views 10

Sunlight does not care what the marketing budget said. A storefront can have a decent product, a clean interior and a capable crew, then lose the first impression before anyone reaches the door because its sign looks tired. That is the plainspoken point behind FASTSIGNS' latest guidance on outdoor sign lifespan. This is not glamorous stuff, but it is operationally...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 128

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 99

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
ArcSpan AMS Nabs Top Honors at The Wires 2026

Updated Category News Views 159

ArcSpan Takes Center Stage with Prestigious Accolade ArcSpan just bagged the Best New Product or Service: Sell Side award at The Wires 2026. This ain't your average pat on the back. Taking place at the ritzy One Marylebone in London, this win springs from an event that celebrates the crème de la crème of digital advertising innovation. A Solid Win Amid The Changing Ad...

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 208

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 229

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovation and Growth: The Future of CODiE Awards 2025

Updated Category News Views 206

The Exciting Future of the CODiE Awards The CODiE Awards, a prestigious program that shines a light on excellence in technology, is stepping into a thrilling new era. With a legacy spanning nearly 40 years, the CODiE Awards are set to expand in 2025, showcasing a wider array of groundbreaking technologies that are reshaping multiple industries, including tech products,...

Continue Reading
aTyr Pharma's Optimistic Trial Data Strengthens Market Position

Updated Category News Views 288

aTyr Pharma's Positive Trial Results Highlight Drug Potential aTyr Pharma (NASDAQ: ATYR) recently reaffirmed its Buy rating and set a price target of $22.00 amid encouraging trial data for its innovative treatment efzofitimod, targeting pulmonary sarcoidosis. This re-evaluation followed the release of a detailed post hoc analysis from its Phase 1/2a clinical trial, which...

Continue Reading
Precision Sapphire Wafers: Redefining Optical Coating Standards

Updated Category News Views 236

Introducing Ultra-Flat Sapphire Wafers for Optical Coating Meller Optics, Inc. has revolutionized the optical industry by launching a full line of optical-grade sapphire wafers. These wafers are fabricated through a proprietary process that ensures extreme flatness, a crucial requirement for high-quality optical applications. Exceptional Specifications of Sapphire Wafers...

Continue Reading
FHLB Dallas and First Security Bank Grant $30K to Local Charity

Updated Category News Views 138

FHLB Dallas and First Security Bank Collaborate to Aid Conway Ministry Center In a significant initiative aimed at community support, representatives from the Federal Home Loan Bank of Dallas (FHLB Dallas) and First Security Bank have come together to award an impressive $30,000 grant to the Conway Ministry Center. This generous funding is designated to enhance shelter...

Continue Reading
Exploring the Future of the Content Management System Market

Updated Category News Views 187

Growing Demand in the Content Management System Market The Content Management System market is witnessing a remarkable evolution, and this growth is driven largely by the increasing need for digital transformation within businesses across various industries. As of recent evaluations, the market size is projected to expand to USD 79.30 billion, following a growth rate of...

Continue Reading